Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pataday vs Claritin in Allergic Conjunctivitis
NCT05265910Phase 4Completed
- Sponsor
- Andover Eye Institute
- Start
- Dec 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of olopatadine in allergic conjunctivitis (AC) (2 arms), sponsored by Andover Eye Institute. Primary endpoint: Ocular Itching Post-CAC. Started Dec 2021; status: completed.
02
Drugs
olopatadine
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT05265910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05265910.